Article
Endocrinology & Metabolism
Judith Everts-Graber, Daniel Lehmann, John-Patrik Burkard, Benoit Schaller, Brigitta Gahl, HansJoerg Haeuselmann, Ueli Studer, Hans-Rudolf Ziswiler, Stephan Reichenbach, Thomas Lehmann
Summary: This study aimed to determine the risk of ONJ in a real-world population, showing a higher incidence rate in patients receiving denosumab therapy compared to those receiving BPs, with previous BP therapy potentially being an additional risk factor for ONJ development.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Dentistry, Oral Surgery & Medicine
D. Hadaya, A. Soundia, I Gkouveris, O. Bezouglaia, S. M. Dry, F. Q. Pirih, T. L. Aghaloo, S. Tetradis
Summary: The discontinuation of antiresorptives for ONJ treatment is dependent on both the type of antiresorptive and the timing of discontinuation, as demonstrated in experiments using rats with zoledronic acid and OPG-Fc. Discontinuing OPG-Fc prior to tooth extraction alleviated ONJ development, while discontinuing either ZA or OPG-Fc in rats with established ONJ did not lead to resolution.
JOURNAL OF DENTAL RESEARCH
(2021)
Review
Endocrinology & Metabolism
Athanasios D. Anastasilakis, Jessica Pepe, Nicola Napoli, Andrea Palermo, Christos Magopoulos, Aliya A. Khan, M. Carola Zillikens, Jean-Jacques Body
Summary: This study evaluates the differences of MRONJ among different patient categories and provides recommendations on how to mitigate the risk and optimally manage MRONJ. The results indicate that patients with advanced malignancies are at a higher risk for MRONJ compared to those with benign bone diseases, but the overall risk is considerably lower than the benefits of treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Jing Peng, Hui Wang, Zhen Liu, Zhen-Liang Xu, Mei-Xia Wang, Qi-Miao Chen, Ming-Li Wu, Xiao-Lei Ren, Qiu-Hua Liang, Fu-Peng Liu, Bo Ban
Summary: This study explored the risk signals of osteonecrosis of the jaw (ONJ) induced by antiresorptive drugs and identified differences in risk factors based on indications. The researchers analyzed data from the FDA's Adverse Event Reporting System and found that the risk of ONJ varied among different indications, with the highest risk observed in metastasis and malignancy. The onset time of ONJ also differed depending on the drug used.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Se Hwa Kim, Young-Kyun Lee, Tae-Young Kim, Yong-Chan Ha, Sunmee Jang, Ha Young Kim
Summary: The study aimed to estimate the incidence of osteonecrosis of the jaw (ONJ) in Korean osteoporosis patients treated with bisphosphonates (BPs) and identified clinical risk factors such as advanced age, diabetes, and rheumatoid arthritis that increase the risk for ONJ.
Article
Dentistry, Oral Surgery & Medicine
Meltem Ozden Yuce, Emine Adali, Gozde Isik
Summary: The study aimed to evaluate the efficacy of growth factors from CGF on the healing process in osteoporotic patients with MRONJ. The results showed that local application of CGF may be an effective approach for surgical treatment of MRONJ in osteoporosis patients by improving tissue regeneration, although not statistically significant.
CLINICAL ORAL INVESTIGATIONS
(2021)
Article
Endocrinology & Metabolism
Akira Taguchi, Hiroshi Hagino, Daisuke Inoue, Naoto Endo, Japan Osteoporosis Soc
Summary: A survey conducted in 2015 by the Japan Osteoporosis Society revealed poor cooperation between physicians and dentists in managing medication-related osteonecrosis of the jaw (MRONJ). A new survey in 2022 showed an increase in cooperation, but regional disparities still exist. Discontinuation of antiresorptive agents is no longer recommended due to increasing fracture rates during discontinuation.
JOURNAL OF BONE AND MINERAL METABOLISM
(2023)
Review
Medicine, General & Internal
Alejandro Lorenzo-Pouso, Jose Bagan, Leticia Bagan, Pilar Gandara-Vila, Cintia M. Chamorro-Petronacci, Pablo Castelo-Baz, Andres Blanco-Carrion, Maria Angeles Blanco-Fernandez, Oscar Alvarez-Calderon, Javier Carballo, Mario Perez-Sayans
Summary: This manuscript critically reviewed the medication-related osteonecrosis of the jaw (MRONJ), updating key terminology, concepts, and current trends in prevention and diagnosis, while examining therapeutic options available. By perusing relevant literature, the review updated the understanding of MRONJ, highlighting gaps in knowledge and emphasizing the need for further research.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Ruxandra Coropciuc, Renaat Coopman, Melisa Garip, Evelien Gielen, Constantinus Politis, Tim Van den Wyngaert, Benoit Beuselinck
Summary: This study found that the incidence of medication-related osteonecrosis of the jaw (MRONJ) after dental extractions is 2.7% per person-year in patients with osteoporosis and 26.4% per person-year in patients with bone metastases. Dental infection as the reason for extraction increases the risk of osteonecrosis in both patient groups. The use of leukocyte and platelet-rich fibrin and antibiotics can significantly reduce the risk, and a longer interval since last administration of antiresorptive agents also reduces the risk.
Article
Cell Biology
Wen Pan, Jianyu Gu, Shihan Xu, Chunmei Zhang, Jinsong Wang, Songlin Wang, Junji Xu
Summary: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious complication in patients with osteoporosis or metastatic bone cancer. The study found that dietary nitrate, abundant in green vegetables, can protect against BRONJ-like lesions in mice. Nitrate intake increased plasma nitric oxide levels, reducing monocyte necrosis and inflammatory cytokine production. The findings suggest that dietary nitrate can inhibit monocyte necroptosis in BRONJ and promote bone remodeling after injury.
CELL PROLIFERATION
(2023)
Article
Medicine, General & Internal
Kazuto Kurohara, Kasumi Shimizu, Taku Murata, Gaku Koizumi, Akira Takigawa, Kokoro Nagata, Kenya Okumura, Naoya Arai
Summary: Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) can significantly impact a patient's quality of life. This study found that the neutrophil-lymphocyte ratio (NLR) has diagnostic value in predicting the risk of hospitalization for inflammatory events among patients with ARONJ.
Article
Dentistry, Oral Surgery & Medicine
Masashi Yamori, Mitsumasa Tamura, Masaki Mikami, Toshio Mori, Masaharu Noi, Yoshisato Machida, Shinya Koshinuma, Gaku Yamamoto
Summary: The study investigated the cooperation between practicing physicians and dentists for preventing MRONJ in patients with osteoporosis in Shiga Prefecture, Japan, and found that the cooperation between physicians and dentists was insufficient.
INTERNATIONAL DENTAL JOURNAL
(2021)
Article
Orthopedics
Wang-yong Zhu, Wei-fa Yang, Leilei Wang, Xinmiao Lan, Zhuo-ying Tao, Jiaxin Guo, Jiankun Xu, Ling Qin, Yu-xiong Su
Summary: This animal study found that an 8-week drug holiday prior to dental extractions can partially recover osteoclastic activity in osteoporosis rats, but does not alleviate the development of MRONJ-like lesion or exacerbate the osteoporotic condition in the femur. Longer-term drug holiday, or combination of drug holiday and other prophylaxes, could be explored in future studies for prevention of MRONJ in patients with osteoporosis.
JOURNAL OF ORTHOPAEDIC TRANSLATION
(2023)
Article
Multidisciplinary Sciences
Kyeong-Mee Park, Namkwon Lee, Jaeyeon Kim, Hyun Sil Kim, Wonse Park
Summary: This study aimed to investigate the preventive effect of teriparatide (TPD) administration on medication-related osteonecrosis of the jaw (MRONJ) before tooth extraction. The results showed that TPD reduced the occurrence of MRONJ in rats treated with zoledronic acid.
SCIENTIFIC REPORTS
(2023)
Article
Dentistry, Oral Surgery & Medicine
A. Lum Han
Summary: The study found that Korean dentists have insufficient awareness of medication-related osteonecrosis of the jaw and lack consistency in responding to patients' drug history prior to dental procedures. There is a need for increased cooperation between dentists and physicians, as well as targeted educational interventions for the dental profession, to reduce the risk of medication-related osteonecrosis of the jaw.
Article
Endocrinology & Metabolism
Satoshi Soen, Takashi Umemura, Tsuyoshi Ando, Toshiaki Kamisaki, Masahiko Nishikawa, Ryoichi Muraoka, Yoshinori Ikeda, Kyoko Takeda, Mitsuharu Osawa, Toshitaka Nakamura
JOURNAL OF BONE AND MINERAL METABOLISM
(2017)
Article
Endocrinology & Metabolism
Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, Hiroaki Ohta, Shunji Takahashi, Satoshi Soen, Akira Taguchi, Toshihiko Nagata, Masahiro Urade, Takahiko Shibahara, Satoru Toyosawa
JOURNAL OF BONE AND MINERAL METABOLISM
(2017)
Article
Gastroenterology & Hepatology
Yuji Mizokami, Kazunori Oda, Nobuo Funao, Akira Nishimura, Satoshi Soen, Takashi Kawai, Kiyoshi Ashida, Kentaro Sugano
Article
Endocrinology & Metabolism
Bente L. Langdahl, Stuart Silverman, Saeko Fujiwara, Ken Saag, Nicola Napoli, Satoshi Soen, Hiroyuki Enomoto, Thomas E. Melby, Damon P. Disch, Fernando Marin, John H. Krege
Article
Endocrinology & Metabolism
Hiroshi Hagino, Satoshi Soen, Toshitsugu Sugimoto, Naoto Endo, Ryo Okazaki, Kiyoshi Tanaka, Toshitaka Nakamura
JOURNAL OF BONE AND MINERAL METABOLISM
(2019)
Article
Endocrinology & Metabolism
Yukari Uemura, Shiro Tanaka, Teruhiko Miyazaki, Mayumi Tsukiyama, Teruki Sone, Akira Taguchi, Satoshi Soen, Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Masao Fukunaga, Hiroaki Ohta, Toshitaka Nakamura, Hajime Orimo, Masataka Shiraki
JOURNAL OF BONE AND MINERAL METABOLISM
(2019)
Article
Endocrinology & Metabolism
Stuart Silverman, Bente L. Langdahl, Saeko Fujiwara, Ken Saag, Nicola Napoli, Satoshi Soen, Hiroyuki Enomoto, Thomas E. Melby, Damon P. Disch, Fernando Marin, John H. Krege
CALCIFIED TISSUE INTERNATIONAL
(2019)
Article
Endocrinology & Metabolism
Akira Taguchi, Yukari Uemura, Takumi Imai, Shiro Tanaka, Hiroaki Ohta, Toshitaka Nakamura, Hajime Orimo, Toshitsugu Sugimoto, Satoshi Soen, Masataka Shiraki
JOURNAL OF BONE AND MINERAL METABOLISM
(2019)
Article
Rheumatology
Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, Takaya Nitta, Naoki Okubo, Harry K. Genant, Desiree van der Heijde
ANNALS OF THE RHEUMATIC DISEASES
(2019)
Article
Endocrinology & Metabolism
Satoshi Soen, Hideaki Kishimoto, Hiroshi Hagino, Teruki Sone, Hiroaki Ohishi, Tsukasa Fujimoto, Emma Sasaki, Sakae Tanaka, Toshitsugu Sugimoto
JOURNAL OF BONE AND MINERAL METABOLISM
(2020)
Article
Endocrinology & Metabolism
Satoshi Soen, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Masako Ito, Tetsuo Nakano, Hiroshi Hagino, Akihiro Hirakawa, Toshio Matsumoto
JOURNAL OF BONE AND MINERAL METABOLISM
(2020)
Article
Endocrinology & Metabolism
Toshio Matsumoto, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Tetsuo Nakano, Masako Ito, Tatsushi Tomomitsu, Akihiro Hirakawa, Satoshi Soen
JOURNAL OF BONE AND MINERAL METABOLISM
(2020)
Article
Endocrinology & Metabolism
Seiji Fukumoto, Satoshi Soen, Tetsuya Taguchi, Takashi Ishikawa, Hisashi Matsushima, Masakazu Terauchi, Shigeo Horie, Toshiyuki Yoneda, Toshitsugu Sugimoto, Toshio Matsumoto
JOURNAL OF BONE AND MINERAL METABOLISM
(2020)
Article
Rheumatology
Tsutomu Takeuchi, Satoshi Soen, Naoki Ishiguro, Hisashi Yamanaka, Sakae Tanaka, Makiko Kobayashi, Naoki Okubo, Takaya Nitta, Yoshiya Tanaka
Summary: New bone erosion predictors in rheumatoid arthritis patients treated with conventional synthetic disease-modifying antirheumatic drugs include seropositivity, elevated inflammatory markers, and baseline erosion score greater than or equal to 3.
MODERN RHEUMATOLOGY
(2021)
Article
Medicine, General & Internal
Satoshi Soen, Saeko Fujiwara, Ryoichi Takayanagi, Kenta Kajimoto, Mika Tsujimoto, Shuichi Kimura, Masayo Sato, John H. Krege, Hiroyuki Enomoto
CURRENT MEDICAL RESEARCH AND OPINION
(2017)